1. Innovation Center for Neurological Disorders, Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China
2. Beijing Key Laboratory of Geriatric Cognitive Disorders, Beijing 100053, China
3. Clinical Center for Neurodegenerative Disease and Memory Impairment, Capital Medical University, Beijing 100053, China
4. Center of Alzheimer’s Disease, Beijing Institute for Brain Disorders, Beijing 100053, China
5. Key Laboratory of Neurodegenerative Diseases, Ministry of Education, Beijing 100053, China
6. National Clinical Research Center for Geriatric Disorders, Beijing 100053, China
Show less
History+
Published Online
2017-11-25
PDF
(5749KB)
Abstract
Increasing evidence in recent years suggests homocysteine (Hcy) is involved in the pathogenesis of Alzheimer’s disease (AD), and that modifying this risk factor may be an alternative approach to delaying or preventing onset of this disease. However, intervention studies suggest inconsistent effects of folic acid supplementation, with or without vitamin B12, on the prevention of incident AD. Studies with Hcy-lowering therapy show beneficial effects of B vitamins in patients with mild cognitive impairment (MCI), especially in those with high Hcy levels. Further studies are needed to confirm elevated Hcy levels as a potentially treatable risk factor for AD.
Jianwei Yang, Jianping Jia.
Homocysteine and Alzheimer’s disease: a literature review.
Journal of Translational Neuroscience, 2017, 2(3): 26-30 DOI:10.3868/j.issn.2096-0689.2017.03.004
PDF
(5749KB)
